Show simple item record

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers : A Systematic Review

dc.contributor.authorCalanzani, Natalia
dc.contributor.authorDruce, Paige E.
dc.contributor.authorSnudden, Claudia
dc.contributor.authorMilley, Kristi M.
dc.contributor.authorBoscott, Rachel
dc.contributor.authorBehiyat, Dawnya
dc.contributor.authorSaji, Smiji
dc.contributor.authorMartinez-Gutierrez, Javiera
dc.contributor.authorOberoi, Jasmeen
dc.contributor.authorFunston, Garth
dc.contributor.authorMessenger, Mike
dc.contributor.authorEmery, Jon
dc.contributor.authorWalter, Fiona M.
dc.date.accessioned2024-02-07T08:39:31Z
dc.date.available2024-02-07T08:39:31Z
dc.date.issued2021-02
dc.identifier225742382
dc.identifier54cfdf7a-ed4d-408e-a3a8-76eb0bba91ec
dc.identifier.citationCalanzani , N , Druce , P E , Snudden , C , Milley , K M , Boscott , R , Behiyat , D , Saji , S , Martinez-Gutierrez , J , Oberoi , J , Funston , G , Messenger , M , Emery , J & Walter , F M 2021 , ' Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers : A Systematic Review ' , Advances in Therapy , vol. 38 , pp. 793-834 . https://doi.org/10.1007/s12325-020-01571-zen
dc.identifier.issn0741-238X
dc.identifier.otherORCID: /0000-0002-5068-2543/work/85100689
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/20142
dc.descriptionFunding This study and the journal’s rapid service fee were supported by the CanTest Collaborative (funded by Cancer Research UK C8640/A23385) of which Fiona M. Walter is Director, Jon Emery is an Associate Director, Mike Messenger is co-investigator, and Natalia Calanzani and Garth Funston are researchers. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Paige Druce, Kristi Milley and Jon Emery are supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4). Mike Messenger is funded by the NIHR Leeds In Vitro Diagnostic Co-operative (UK). No Open Access Fee was received by the journal for the publication of this article.en
dc.format.extent37
dc.format.extent1210740
dc.language.isoeng
dc.relation.ispartofAdvances in Therapyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleIdentifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers : A Systematic Reviewen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1007/s12325-020-01571-z
dc.identifier.urlhttps://doi.org/10.1007/s12325-020-01571-zen
dc.identifier.vol38en


Files in this item

Thumbnail
Name:
Doherty_etal_CEBP_Alpha_Reduct ...
Size:
333.6Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record